Physician’s take: In head-to-head trials, tirzepatide produced more average weight loss than semaglutide — but “more effective on average” is not the same as “right for you.” Tolerability, medical history, and cost matter just as much.
The short version
Both medications are once-weekly injections that mimic gut hormones to reduce appetite. The key difference:
- Semaglutide (Wegovy, Ozempic) activates one receptor: GLP-1.
- Tirzepatide (Zepbound, Mounjaro) activates two: GLP-1 and GIP.
That second receptor is the reason tirzepatide has drawn so much attention — and the reason the comparison deserves more nuance than a headline.
What the trials actually show
Semaglutide (Wegovy): In the STEP trial program, patients on the full 2.4 mg weekly dose lost an average of about 15% of body weight over 68 weeks, combined with lifestyle changes.
Tirzepatide (Zepbound): In the SURMOUNT-1 trial, patients on the highest dose lost an average of about 21% of body weight over 72 weeks.
Head-to-head: The SURMOUNT-5 trial compared the two directly in adults with obesity. Tirzepatide produced significantly greater average weight loss than semaglutide.
Averages, though, hide wide individual variation. In every one of these trials, some patients on semaglutide lost more than the average tirzepatide patient — and vice versa.
Side effects: more similar than different
Both drugs share the same GLP-1 side-effect profile:
- Nausea, vomiting, diarrhea, or constipation — most common, usually worst during dose increases
- Decreased appetite (the intended effect)
- Occasional fatigue or reflux
Tirzepatide’s higher efficacy comes with a trade-off: gastrointestinal side effects tend to be somewhat more frequent, particularly at higher doses. Both carry the same class boxed warning about thyroid C-cell tumors observed in rodent studies, and both require screening for pancreatitis history and certain thyroid conditions.
Who might suit which?
There is no universal answer, but physicians weigh factors like these:
- Tirzepatide may be favored when maximum weight loss is the priority and the patient tolerates dose escalation well. It also has an FDA approval for moderate-to-severe sleep apnea in adults with obesity — relevant if that’s part of your picture.
- Semaglutide may be favored when a patient has done well on it before, when tolerability is the main concern, when cardiovascular risk reduction matters (semaglutide has the strongest cardiovascular-outcomes data in the class), or when insurance covers one but not the other.
Cost and availability are real-world tiebreakers. Insurance formularies often cover one brand and not the other, and that practical constraint shapes many decisions.
The bottom line
This is a decision for a physician visit, not a comment section. The right medication depends on your BMI, comorbidities, medication history, side-effect tolerance, and coverage — evaluated together, by a doctor who knows your case.
Frequently asked questions
Can I switch from semaglutide to tirzepatide?
Yes — switching is common, usually when weight loss has plateaued or side effects are an issue. Your physician will plan the transition, including where to start dosing on the new drug.
Is tirzepatide just “stronger Ozempic”?
Not exactly. It’s a different molecule with dual-receptor action. “Stronger” captures the average efficacy difference, but the drugs differ in more than potency.
Which one has fewer side effects?
On average, semaglutide’s GI side effects are somewhat milder, but individual experience varies enormously. Titration speed can be adjusted for either drug.
Does insurance prefer one over the other?
Often, yes — formularies change frequently. We check coverage as part of your evaluation and discuss self-pay options when insurance won’t cover treatment.
What does treatment cost without insurance?
Call (573) 255-2089 for current pricing.
Can I do this entirely by telemedicine?
If you’re in Missouri or Illinois, yes — evaluation and follow-ups can be done virtually.
This article is for educational purposes and is not medical advice. GLP-1 medications require a prescription and physician supervision. Dr. Vishon J Subramani, M.D., Bariatric & Metabolic Institute — (573) 255-2089. In-person care in Sikeston, MO; telemedicine across Missouri and Illinois.
